| 翻訳と辞書 |
| ceftobiprole ： ウィキペディア英語版 |
ceftobiprole
Ceftobiprole (Zeftera/Zevtera) is a fifth-generation cephalosporin antibiotic with activity against methicillin-resistant ''Staphylococcus aureus'', penicillin-resistant ''Streptococcus pneumoniae'', ''Pseudomonas aeruginosa'', and enterococci. It was discovered by Basilea Pharmaceutica and was developed by Johnson & Johnson Pharmaceutical Research and Development. It has been shown to be statistically noninferior to the combination of vancomycin and ()] for the treatment of skin and soft tissue infections.
It has been described as a fifth-generation cephalosporin, though acceptance for this terminology is not universal.
==Pharmacology==
Like other cephalosporins, ceftobiprole inhibits bacterial growth by blocking penicillin-binding protein, a key enzyme involved in cell wall synthesis. Ceftobiprole inhibits the 2a penicillin-binding protein (PBP) of methicillin-resistant ''Staphylococcus aureus'' and the 2x PBP of ''Streptococcus pneumoniae'',〔 as well as the classic PBP-2 of MSSA. Ceftobiprole is resistant to staphylococcal β-lactamase.〔
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「ceftobiprole」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|